Hanmi Pharmaceutical is making significant strides in expanding its global footprint with the recent agreement to supply efpeglenatide, a groundbreaking treatment for obesity and metabolic diseases, to Mexico’s Laboratorios Sanfer. This partnership not only highlights Hanmi’s innovative capabilities but also addresses pressing health challenges in a country grappling with high obesity rates.
Strategic Partnership Dynamics
Under the new agreement, Hanmi will provide efpeglenatide along with its Dapalon Family products, while Sanfer will manage the regulatory approval process, marketing, distribution, and sales in Mexico. This collaborative effort leverages Hanmi’s expertise in drug formulation and Sanfer’s robust presence in the Latin American pharmaceutical market.
Addressing Public Health Concerns
Mexico faces a severe obesity crisis, with prevalence rates soaring to 36.86%. The country also contends with a diabetes prevalence of 16.4%. As healthcare demands evolve, there is a growing need for treatments that extend beyond mere weight loss. Efpeglenatide’s dual potential for weight management and blood glucose regulation positions it as a critical player in addressing these intertwined health issues.
Sanfer’s Established Market Presence
Founded in 1941, Sanfer has become the largest privately held pharmaceutical company in Mexico. With a vast distribution network that spans over 20 countries, including the United States, Sanfer’s recent acquisition of Probiomed has further solidified its status in the biopharmaceutical realm. This extensive reach enables the company to effectively promote and distribute Hanmi’s products across the region.
Long-term Collaboration Prospects
The partnership between Hanmi and Sanfer is expected to grow beyond the initial launch of efpeglenatide. Future collaborations may include additional product launches and joint marketing initiatives focused on metabolic disease treatments. This strategic approach will allow both companies to maximize their resources and expertise, ultimately enhancing patient access to innovative therapies.
Leadership Perspectives
Ricardo Amtmann, Sanfer’s CEO, emphasized the importance of this collaboration, stating that it aligns with the company’s mission to enhance patient care through high-quality, innovative products. Given that healthcare expenditures account for 34.6% of household income in Mexico, the partnership aims to improve accessibility to essential treatments like efpeglenatide, which addresses urgent public health challenges.
In parallel, Jae-hyun Park, CEO of Hanmi Pharmaceutical, reflected on the significance of the agreement, recognizing it as a testament to Hanmi’s research and development prowess on an international stage. The partnership is timely, coinciding with Mexico’s governmental focus on enhancing healthcare services and managing chronic diseases more effectively.
Regulatory Progress
As of December 17, 2025, Hanmi has submitted its regulatory application for efpeglenatide to the Ministry of Food and Drug Safety. Additionally, the company is advancing its research with a Phase 3 clinical trial evaluating the combination of efpeglenatide with SGLT-2 inhibitors and metformin, which received approval on January 21, 2026. This proactive approach signifies Hanmi’s commitment to broadening the therapeutic applications of efpeglenatide, with obesity approval anticipated in the latter half of 2026 and a diabetes indication expected by 2028.
Conclusion
The collaboration between Hanmi Pharmaceutical and Sanfer marks a pivotal moment in the fight against obesity and diabetes in Mexico. By combining their strengths, these companies are poised to make a substantial impact on public health, providing innovative solutions to pressing healthcare challenges. This strategic partnership not only signifies a leap forward in Hanmi’s global expansion but also promises improved health outcomes for millions in Mexico.
- Hanmi Pharmaceutical partners with Sanfer for efpeglenatide distribution in Mexico.
- The agreement addresses obesity and diabetes, pressing health issues in the country.
- Sanfer’s established market presence enhances the collaboration’s potential.
- Future growth opportunities are anticipated, expanding the partnership beyond initial offerings.
- Regulatory progress indicates Hanmi’s commitment to timely product launches.
Read more → www.manilatimes.net